A key conceptual shift is viewing ctDNA not as a statistical risk marker, but as direct detection of molecular residual disease (MRD). This framing, similar to how a CT scan identifies metastases, explains its high positive predictive value and justifies its use in making critical treatment decisions.

While the need for prospective trials dominates the ctDNA discussion, a more fundamental obstacle is the lack of standardization between assay types (e.g., tumor-informed vs. agnostic). Without a common measurement approach, data from disparate trials cannot be pooled to create a universally accepted surrogate endpoint for regulatory approval.

ctDNA testing (liquid biopsy) is more effective than tissue biopsy for identifying ESR1 mutations. It samples DNA from all metastatic sites, capturing the disease's genetic heterogeneity and reflecting the most active resistance mechanisms, unlike a single-site needle biopsy which can miss them.

ESR1 mutations in breast cancer are acquired alterations, meaning they can be missed by a single test. The speaker advocates for serial testing, especially after disease progression, using blood-based ctDNA analysis. This dynamic monitoring approach is essential for identifying patients who become eligible for targeted therapies over time.

Circulating tumor DNA (ctDNA) testing is described as unequivocally the most prognostic tool available for colorectal cancer. Patients who remain serially negative have a minimal recurrence risk, while a positive result almost universally predicts a future clinical recurrence by 6-8 months.

An individual tumor can have hundreds of unique mutations, making it impossible to predict treatment response from a single genetic marker. This molecular chaos necessitates functional tests that measure a drug's actual effect on the patient's cells to determine the best therapy.

The original Signatera assay used 16 personalized probes based on whole-exome sequencing to find ctDNA. The next-generation version, based on whole-genome sequencing, expands this to 64 probes. This is expected to significantly increase sensitivity, detect molecular relapse earlier, and provide a longer window for clinical intervention.

The next major advance in adjuvant kidney cancer will be a biomarker to select who needs treatment. The key is developing a Minimal Residual Disease (MRD) test based on the epigenome (e.g., chromatin modifications) rather than just ctDNA mutations. This is because the critical biological signals in RCC are found in epigenetic regulation, not just the genome.

Tumor-informed assays like Signatera sequence a patient's tumor to create a personalized test, making it highly sensitive but taking 3-4 weeks. Tumor-uninformed assays are faster (1 week) but less sensitive as they screen for a generic panel of cancer mutations.